The Road to Pamplona - Stronger together in CNS genetic medicine.

Gene therapy for the brain has arrived. What happens next is a conversation the whole field needs to have.

Broadreach Global · Gene4Neuro Series · Opening post ·

A decade ago, if you told a neurologist that a single intravenous infusion could halt the progression of a fatal infant disease — reprogram a faulty gene, and let a child walk who would otherwise never have stood — they might have called it science fiction.

It isn't. It happened. And for those of us working at the intersection of neuroscience innovation, investment, and industry, it changed the entire frame of what is possible.

At Broadreach Global, we sit at a particular vantage point in this field. We are not gene therapy scientists. We spend our days inside the networks where research, clinical development, investment, business development and licensing, policy, and patient advocacy overlap and sometimes collide. There can be both friction, and synergies. As part of this, we build forums where the scientists, the CEOs, the investors, the clinicians, and the families can be in the same room, having the same honest conversation. And what we hear from across our network, consistently and unmistakably, is that we are at an inflection point.

The approval of Zolgensma for spinal muscular atrophy was not just a milestone for SMA families. It was a proof of concept for an entire approach to medicine: that a genetic defect in the nervous system, one that had been a death sentence, could be corrected at source. Since then, the acceleration has been real. More CNS gene therapy programs have entered clinical development in the last five years than in the preceding two decades combined. The range of modalities has expanded well beyond viral gene replacement — antisense oligonucleotides, RNA therapeutics, antibody-based approaches, and next-generation vector platforms are all advancing. The disease targets have broadened, from ultra-rare pediatric conditions toward the harder, larger challenges of Parkinson's, ALS, Alzheimer's, Huntington's, and frontotemporal dementia.

Investment has followed. Deals have been struck. Talent has moved in from adjacent fields. The field looks, from the outside, like a success story.

From the inside — from the conversations we are privileged to have across our network of researchers, clinicians, biotech founders, investors, industry executives, and patient families — the picture is more complicated. And more interesting.

Delivery to the brain remains one of the defining unsolved problems. The blood-brain barrier does not bend to ambition or clinical timelines. Manufacturing complexity is a genuine constraint, not a detail — and the cost structures it creates have real consequences for which patients, in which countries, on which timelines, will ever access these therapies. Safety has not been a closed chapter: serious adverse events have punctuated the clinical landscape, demanding that the field confront the limits of what preclinical models can predict and what it means to be truly honest about risk with patients and regulators. Regulatory frameworks are still being written, and not always in the directions or at the speeds the field needs. Pricing and access in a world where approved therapies can cost more than most families earn in a lifetime remain genuinely unresolved — and the pressure will only grow as the field moves from ultra-rare diseases toward larger neurological populations. Clinical adoption at scale remains another challenge.

These are not reasons for pessimism. They are reasons why we need the kind of honest, expert, multi-stakeholder conversation that moves a field forward faster than any single organization or institution can on its own.

That conversation is exactly what we are building, together with our partners and network — in the Gene4Neuro initiative, and starting here.

Over the next several weeks, on the road to Gene4Neuro in Pamplona (2 - 4 June, CIMA) , we will publish a series of posts touching on the science and the strategy, the successes and the setbacks, the debates about delivery, modalities, clinical development, pricing, safety, and what it actually takes to get genetic medicines to patients with neurological disease. We will draw on our network — the researchers, clinicians, investors, advocates, and industry leaders who are doing this work — for insight, context, and opinion. Where the field agrees, we will say so. Where it does not, we will say that too.

We write from a position of deep respect for everyone building in this space. The science is extraordinary. The patient need is urgent. And the decisions being made now — about which vectors, which delivery routes, which diseases, which business models — will define which patients get access to genetic medicines for brain disease in the next decade, and which do not.

That is a conversation worth having in public. Follow along. Disagree. Add what we miss. Join in the conversation right here.

The Gene4Neuro community is being built one exchange at a time — and this is where it starts.